AS Birch Grove (formerly Ascribe Capital)

AS Birch Grove (formerly Ascribe Capital)AS Birch Grove (formerly Ascribe Capital)
AB

AS Birch Grove (formerly Ascribe Capital)

Invests in distressed middle-market companies and corporate credit opportunities across North America and Europe.

2006PE$1.8B AUMNew York, United States
Rate

About

Ascribe Capital was a private investment firm that focused on corporate credit opportunities within North America and Europe. They managed a diverse portfolio across various financial vehicles, including an opportunistic hedge fund, private credit vehicles, par credit vehicles, and a Collateralized Loan Obligation (CLO) platform. The firm specialized in investing in the debt and equity securities of middle-market companies that were distressed or undergoing operational, financial, or other stress. In July 2021, Ascribe Capital merged with Birch Grove Capital to form AS Birch Grove, managing approximately $5 billion in assets.
Frequently asked

What type of investor is AS Birch Grove (formerly Ascribe Capital)?

Ascribe Capital was a private investment firm that focused on corporate credit opportunities within North America and Europe. They managed a diverse portfolio across various financial vehicles, including an opportunistic hedge fund, private credit vehicles, par credit vehicles, and a Collateralized Loan Obligation (CLO) platform. The firm specialized in investing in the debt and equity securities…

What kind of firm is AS Birch Grove (formerly Ascribe Capital)?

AS Birch Grove (formerly Ascribe Capital) is a PE.

What is AS Birch Grove (formerly Ascribe Capital)'s assets under management?

AS Birch Grove (formerly Ascribe Capital) manages approximately $1.8B in assets.

Where is AS Birch Grove (formerly Ascribe Capital) based?

AS Birch Grove (formerly Ascribe Capital) is based in New York, United States.

What sectors does AS Birch Grove (formerly Ascribe Capital) focus on?

AS Birch Grove (formerly Ascribe Capital) focuses on Distressed Debt, Corporate Credit.

Comments

No comments yet. Be the first to share your take.